GRN and frontotemporal dementia: In summary, these studies suggest that there is a sequence of changes seen in different biomarkers of genetic FTD prior to clinical onset of symptoms: the earliest of these are likely to be a number of plasma (and CSF) markers (although apart from plasma progranulin concentration this remains unproven) followed by markers of functional and structural connectivity, then grey matter atrophy, and finally mild neuropsychometric abnormalities in proximity to the first symptoms.